Assessment of fracture risk tools in care home residents: a multi-centre observational pilot study.

BACKGROUND: Fragility fractures are common in care home residents but established tools have not been tested in this population. AIM: To identify the most practicable tool for use. METHODS: DESIGN: Multicentre prospective observational cohort pilot study. SETTING: 18 care homes in Boston, UK. ASSESSMENTS: fragility risk score at baseline with FRAX, QFractureScore, Garvan nomogram, body mass index and TUGT for each participant. OUTCOMES: falls, fractures, combined falls & fractures. Follow-up; 12 months. RESULTS: 217/618 (35%) residents in the 18 care homes were enrolled. 147 (68%) had mental capacity,70 (32%) did not. There were 325 falls and 10 fractures in participants during the study. At the same time there were 1671 falls and 103 fractures in residents not participating in the study. Multiple regression analyses showed that only age had a statistically significant association with falls (χ2(1) = 5.7775, p = 0.0162), fractures (χ2(1) = 4.7269, p = 0.0297) and combined falls & fractures (χ2(1) = 4.7269, p = 0.0297). C-statistics were: falls; FRAX 0.544, BMI 0.610, QFractureScore 0.554, Garvan nomogram 0.579, TUGT 0.656, fractures; FRAX 0.655, BMI 0.708, QFractureScore 0.736, Garvan nomogram 0.712, TUGT 0.590, combined falls and fractures, c-statistics were same as for fractures. Fifty-four participants (25%) died during follow-up. Charlson comorbidity index predicted mortality, R2 = 0.021 (p = 0.034). CONCLUSIONS: QFractureScore, BMI and Garvan nomogram were good predictors of fractures and combined falls and fractures Only age had statistically significant association with the outcomes. No tool was good predictor of falls.

Coiling occlusion of the vertebral artery for a patient with recurrent posterior circulation TIAs.

Recurrent posterior circulation infarcts frequently involve multiple vascular territories, suggesting an embolic source. We describe a patient with left vertebral artery occlusion who had recurrent transient ischaemic attacks due to cerebral embolization originating from the occluded vertebral artery in spite of optimal anticoagulant and antithrombotic treatment. This was successfully managed by coiling occlusion of the vertebral artery with no recurrence of symptoms over one year of follow-up. To our knowledge, this is the first report of coiling occlusion in the treatment of recurrent vertebral artery embolization.

The 2010 British Association of Stroke Physicians Survey of interventional treatments for stroke in the United Kingdom.

INTRODUCTION: The UK National Stroke Strategy (Department of Health 2007) states that patients should have access to a stroke service with neurointerventional capacity. This survey was conducted by the Clinical Standards Committee of the British Association of Stroke Physicians to get a snapshot of the availability of interventional treatments for stroke in the United Kingdom. METHODS: Questionnaires covering availability of endovascular treatments for stroke, e.g. intra-arterial thrombolysis and mechanical thrombectomy, were emailed to all British Association of Stroke Physicians members in October 2010. Where more than one response was received from the same hospital, the data were only entered once. If there was a discrepancy between different respondents for the same hospital, details were cross-checked with the respondents to ensure accuracy. RESULTS: Responses were received from 58 hospitals in England, Scotland, Wales, and Northern Ireland. Intra-arterial thrombolysis and/or mechanical thrombectomy were available in 23 hospitals. Of these, three had not performed any procedures in 2010. Twenty centres had conducted a mean (range) of eight (2-20) procedures during the 10-month period. Thirty-five hospitals were not offering endovascular treatments. Sixteen of these were not referring patients to centres which could provide interventional treatments. Hospitals offering endovascular treatments had a mean (range) of 5.2 (2-12) stroke physicians, 2.3 (0-4) interventional neuroradiologists, and 3.6 (0-9) noninterventional neuroradiologists. Only two hospitals providing interventions had four or more interventional neuroradiologists. CONCLUSIONS: Only a small number of hospitals in the United Kingdom provide interventional treatments for stroke. Almost 50% of hospitals not providing interventions had no processes in place for referral to providers.

Spasticity and contractures at the wrist after stroke: time course of development and their association with functional recovery of the upper limb.

OBJECTIVE: To investigate the time course of development of spasticity and contractures at the wrist after stroke and to explore if these are associated with upper limb functional recovery. DESIGN: Longitudinal observational study using secondary data from the control group of a randomized controlled trial. SETTING: The Acute Stroke Unit at the University Hospital of North Staffordshire. SUBJECTS: Patients without useful arm function (Action Research Arm Test - ARAT) score of 0 within 6 weeks of a first stroke. MAIN MEASURES: Spasticity was measured by quantifying muscle activity during passively imposed stretches at two velocities. Contractures were measured by quantifying passive range of movement and stiffness. Upper limb functional movement was assessed using the ARAT. All assessments were conducted at baseline, and at 6, 12, 24 and 36 weeks after recruitment. RESULTS: Thirty patients (43% male, median age 70 (range 52-90) years, median time since stroke onset 3 (range 1-5) weeks) were included. Twenty-eight (92%) demonstrated signs of spasticity throughout the study period. Participants who recovered arm function (n = 5) showed signs of spasticity at all assessment points but did not develop contractures. Patients who did not recover useful arm function (n = 25) had signs of spasticity and changes associated with contracture formation at all time points tested. CONCLUSION: In this group of patients who had no arm function within the first 6 weeks of stroke, spasticity was seen early, but did not necessarily hinder functional recovery. Contractures were more likely to develop in patients who did not recover arm function.

Computational modeling of a new thrombectomy device for the extraction of blood clots.

Thrombectomy devices have been developed as an alternative means for clot removal. A number of devices using a variety of methods to remove the clot are now available. This chapter covers the analysis and research into a device recently developed in the UK, called a "GP" thrombus aspiration device (TAD). Presented in this work is the development of a model of this device, as well as its simulation and interpretation of the results obtained with the potential for helping in optimizing its operation for future use. The simulation model that is presented can be used in showing the potential performance of the "GP" TAD device under different conditions of blood flow and size of blood clot, obtaining the minimum pressure necessary to extract the clot and to check that both this pressure and the time required to complete the operation are reasonable for potential use in clinical situations patients, and are in line with experimentally obtained data.

Conocimiento, información y toma de decisiones en pacientes con cáncer en el Gran Buenos Aires sur / No disponible

Introducción: debemos revelar el diagnóstico al paciente con cáncer? Y su angustia? Y su temor? El paciente tiene derecho a conocer su enfermedad pero también tiene derecho a no saberlo. Los datos bibliográficos indican que, a pesar de la predisposición de la población y el paciente a conocer su diagnóstico, hay otras elementos condicionando esta información, tanto de parte del paciente y la familia como del personal sanitario. Dado que existen pocos estudios en nuestro país al respecto, creemos útil conocer las necesidades de nuestra población y su participación en la toma de decisiones como aporte hacia una mejor comunicación. Objetivo: pesquisar el conocimiento del paciente oncológico acerca de su enfermedad, su necesidad sobre la información a recibir y el grado de participación en la toma de decisiones. Metodología: estudio descriptivo, observacional, transversal usando un cuestionario escrito semiestructurado y autoadministrado. Resultados: de 122 pacientes encuestados, 77,8% se sabía portador de un cáncer cuando se realizó la encuesta, el 80,32% se manifestó satisfecho con la información recibida, 77,8% deseaba saber todo acerca de su enfermedad incluido malas noticias y el 85,24% prefería que la decisión fuera tomada exclusivamente por los médicos aún con los conocimientos actuales de su enfermedad. Conclusiones: en la población estudiada, los datos obtenidos exhiben resultados similares a la literatura internacional pero llamó la atención el alto porcentaje de pacientes que delegaba el proceso de toma de decisiones en el equipo clínico-quirúrgico u oncológico. Se plantean posibles causas y alternativas para facilitar una conducta activa en este último punto (AU)

Background: must we reveal their diagnosis to cancer patients? And the anguish? And the fear? The patient has the right to be informed about his or her illness butal so has the right to not know about it. The literature shows that other factors must be taken into consideration regarding such information, both related to the patient and his/her family and the healthcare staff. There are few studies about these issues in our country. We believe that knowing information needs and preferences is useful for better communication with our patients and their involvement in decision making. Objective: to assess the knowledge of cancer patient about their illness, and their information needs and preferences regarding their participation in treatment decisions. Method: a descriptive, observational, crossover survey using a semistructured, self-administered written questionnaire. Results: the survey included 122 patients -77.8% knew they had a neoplastic disease at the time of survey, 80.32% were satisfied with the information received, 77.8% wanted all the information available, both good andbad news, and 85.24% preferred to delegate treatment decisions to theirphysicians, even after having received information on their illness. Conclusions: in this population our results are similar to those in the international literature, but the high percentage of patients delegating decision-making to their physicians drew our attention. We point out thepossible causes and comment alternatives to help patients play an activerole in this last issue (AU)

Effect of hemiparetic stroke on pulse oximetry readings on the affected side.

BACKGROUND AND PURPOSE: Hypoxia is common after stroke, and monitoring by pulse oximetry is suggested in the acute phase. Physical changes on the affected side or intravenous infusions may affect oximeter readings. This study was designed to test whether pulse oximetry recordings are the same on the affected and nonaffected sides in stroke patients. METHODS: Oxygen saturation (SpO(2)) and heart rate (HR) were assessed simultaneously in the left and right hands in patients with hemiparetic stroke over a 3-hour period with 2 Minolta Pulsox-3i oximeters attached to the index fingers. RESULTS: Fifteen patients (53% men; 67% left hemiparesis; mean age, 73 years [SD, 7.5 years]) were recruited. HR and SpO(2) (12 measurements per minute) were monitored. The maximum difference between simultaneous left and right arm readings was 2% SpO(2). HR fluctuated more, but no affected/nonaffected side pattern was seen. Means for each patient of HR and SpO(2) for the affected and nonaffected sides were compared by t tests. Mean SpO(2) was 96% (SD, 1%) on both sides. Mean HR was 81 bpm (SD, 11 bpm) on the affected side and 80 bpm (SD, 10 bpm) on the nonaffected side. There was no significant difference between the 2 sides for either parameter (n=15; P=0.86 for SpO(2) and P=0.91 for HR). CONCLUSIONS: Oximeters can be attached to either the affected or nonaffected side in hemiparetic stroke.

Ageing of the heart.

Ageing of the heart is associated with a number of characteristic morphological, histological and biochemical changes. However, not all observed changes with age are associated with a deterioration in function. The high prevalence of hypertension and ischaemic heart disease makes distinction between normal ageing changes and the effects of underlying cardiovascular disease processes difficult. In this review, an attempt has been made to separate age-related changes from those related to disease, and to outline their significance for cardiac performance. Disease-independent changes in the ageing heart which are associated with a reduction in function include a reduction in the number of myocytes and cells within the specialised conduction tissue, the development of cardiac fibrosis, a reduction in calcium transport across membranes, lower capillary density and decreases in the intracellular response to beta-adrenergic stimulation. Other characteristic changes, such as epicardial fat deposition and 'brown atrophy' due to intracellular lipofuscin deposits, appear to be merely symptomatic of the ageing process without any obvious effects on function. Some of the age-associated changes in the heart can be reversed, at least partially, by exercise or specific drugs. It remains, however, unclear whether this would result in any definite advantages for the individual. The mechanisms guiding proliferation or non-proliferation of myocytes and the development of fibrosis are current topics for research and may lead to new preventive approaches to ageing processes in the heart.

The effect of afterload and angiotensin II on proto-oncogene mRNA levels in the isolated working rat heart.

OBJECTIVES: The proto-oncogenes c-fos, c-myc and H-ras have been shown to rise in a characteristic pattern in the left ventricle undergoing hypertrophy in the coarctation model of experimental hypertension and there is some evidence to suggest that they might play a role in the initiation of hypertrophic growth. However, in vivo studies do not discriminate between the direct effects of pressure and pressure-independent trophic stimuli such as angiotensin II. To examine these influences separately we studied isolated working hearts exposed to different afterloads in the presence or absence of angiotensin II. METHODS: Hearts from normotensive female Wistar rats were perfused with a modified Krebs-Henseleit solution, with and without angiotensin II (100 nmol/1) and exposed to low (60 mmHg) or high (140 mmHg) afterload (n > 17/group). Proto-oncogene mRNA induction in the left ventricle was assessed by Northern blot analysis. RESULTS: Aortic pressures were 101 +/- 14/63 +/- 6 mmHg (mean +/- s.d.) with low and 175 +/- 13/93 +/- 20 mmHg with high afterload; hearts in both groups maintained a stable cardiac output over 240 min, except for high afterload hearts not perfused with angiotensin II, which showed a 59% drop by the end of the experiment (P < 0.001). There was a 50% (32%, 72%) (geometric mean and 95% confidence interval) increase of c-myc and 54% (27%, 86%) increase in c-fos, but a 32% (25%, 40%) suppression of H-ras with high (140 mmHg) as compared with low (60 mmHg) afterloads (P < 0.0001 for each). There was no significant difference in c-myc and c-fos induction with different levels of high afterload (110, 120, 140 mmHg), but for H-ras suppression progressively increased with increasing afterload (P = 0.003). At high afterload, levels of c-fos rose at 30 min and peaked at 60 min, c-myc continued to rise up to 240 min, and H-ras was suppressed at all four time points. The addition of angiotensin II (100 nmol/l) to the perfusate resulted in 18% (6%, 28%; P = 0.006) lower c-myc levels, 12% (-6%, 28%; P = 0.18) lower c-fos levels and an 11% (-0.1%, 24%; P = 0.056) increase of H-ras. CONCLUSION: The isolated perfused working rat heart is capable of performing stably for a period of at least 240 min at high afterload pressures comparable to those encountered in hypertension. A proto-oncogene induction similar to that seen in the hypertrophying heart can be induced by increased pressure alone, without the mediating effects of circulating angiotensin II. Hearts perfused with angiotensin II showed a more stable performance at high levels of afterload which was associated with a minor attenuation of pressure-induced changes in proto-oncogene expression.

Madness and care in the community: a medieval perspective.

Care in the community for insane people today is more a matter of expert provision than communal support. In consequence, although they are no longer confined to hospital, mentally ill people largely remain marginalised in a society that does not have the resources, nor often the inclination, to take responsibility for their care. The experience of insane people in medieval England seems to have been of a different order, as shown by a particularly well documented case dating from 1383. From the late 13th century congenital idiots were protected by law. Care of lunatics, by contrast, was primarily the responsibility of the family. However, where the family could not or was unwilling to provide, provision was made by the crown. Through the instrument of the inquisition, the diagnosis and social circumstances of each case were determined by commissioners in consultation with a local jury and all interested parties, including the subject himself or herself. The best interests of the subject remained a prime concern, and the settlement that was ordained was tried and enforced in law. The process was confined to those with real or personal estate, but it encompassed poor as well as rich and proved, through the close identity of the local community with the process, to be a sophisticated and effective mechanism for maintaining and sustaining insane people. Unlike today, care in the community was a communal activity that ensured a truly public provision for those who could not look after themselves.

Anticholinergic premedication for fibreoptic bronchoscopy.

Atropine is routinely used as part of the premedication regimen for fibreoptic bronchoscopy. This study was performed, firstly, to evaluate the effect of anticholinergic agents on the ease of bronchoscopy, haemodynamic parameters and patient comfort during the procedure; and secondly, to compare atropine with glycopyrrolate, a newer acetylcholine antagonist which is claimed to cause less tachycardia and sedation, whilst suppressing salivation more effectively. One hundred and ninety consecutive patients were randomly allocated to three treatment groups: diazepam 5 mg; diazepam 5 mg + atropine 600 micrograms; and diazepam 5 mg + glycopyrrolate 300 micrograms. Diazepam was given orally one hour before bronchoscopy, and glycopyrrolate/atropine intramuscularly 30 min before bronchoscopy. All patients received thalamonal intravenously, lignocaine gel into one nostril, and lignocaine by transtracheal injection just prior to the procedure. The incidence of bronchoscopy related haemodynamic problems was similar in all three groups. Troublesome coughing, as observed by the operator, was less frequent with glycopyrrolate (control 51%, atropine 42%, glycopyrrolate 30%), as was patient movement (40%, 32%, 19%, respectively). Uncomfortable dryness of the mouth was most common with glycopyrrolate (37%, 32%, 66%, respectively), but overall assessment of discomfort, and the number of patients who would agree to a repeat bronchoscopy (73%, 76%, 70%, respectively) were very similar in all three groups. In conclusion, the differences between the three groups were slight. Glycopyrrolate made the bronchoscopy slightly easier for the operator because of significantly improved cough and movement suppression, though atropine was marginally preferable in terms of patient comfort.

Investigation of the effects of intravenous magnesium sulphate on cardiac rhythm in acute myocardial infarction.

OBJECTIVE: To examine the effect of doubling serum magnesium concentration on the incidence of arrhythmias in patients with suspected acute myocardial infarction. DESIGN: Randomised double blind clinical trial. SETTING: Coronary care unit of a teaching hospital. PATIENTS: Clinical data were collected on 2316 randomised patients with suspected acute myocardial infarction. Holter monitoring was performed in a subgroup of 70 patients and analysed in 48 patients in whom acute myocardial infarction was confirmed. INTERVENTIONS: By random allocation, patients received either an intravenous loading dose of 8 mmol magnesium sulphate over five minutes plus 65 mmol over the next 24 hours, or equal volumes of saline. MAIN OUTCOME MEASURES: (a) Clinically documented arrhythmias; (b) use of antiarrhythmic treatments, cardioversion, and insertion of a pacemaker; (c) incidence of all abnormal rhythms during Holter monitoring. RESULTS: In the main trial the incidence of rhythm disturbance while in the coronary care unit (expressed as the odds ratio (OR) for magnesium: placebo and its 95% confidence interval) was not significantly different between treatment groups for ventricular fibrillation (OR 0.74; 0.46 to 1.20), ventricular tachycardia (OR 0.87; 0.63 to 1.20), supraventricular tachycardia (OR 0.69; 0.38 to 1.26), atrial fibrillation (OR 0.92; 0.69 to 1.23), or heart block of any degree (OR 1.17; 0.83 to 1.65). Sinus bradycardia was significantly more common in the magnesium group (OR 1.38; 1.03 to 1.85; p = 0.02). These findings were corroborated by the use of treatments for rhythm disturbance and the data from Holter monitoring. CONCLUSION: The regimen of intravenous magnesium sulphate used here had no significant effect on arrhythmia in acute myocardial infarction. The reduction in mortality that has been shown with this form of treatment is not attributable to suppression of life threatening rhythm disturbances.